ResApp Provides Update on US Clinical Study

View printer-friendly version ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today provided an update on its US clinical study program. ResApp is currently in advanced...

ResApp Announces Positive Preliminary Results from Adult Clinical Study

View printer-friendly version High accuracy achieved for the diagnosis of chronic obstructive pulmonary disease (COPD), asthma and pneumonia in adults, equivalent to overall accuracy in children 92%-100% accuracy for distinguishing adult patients with COPD, asthma and...

ResApp Provides Australian Adult Study Enrolment Update

View printer-friendly version ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it has enrolled 322 adult patients (236 confirmed respiratory disease cases...